Literature DB >> 22149573

Medical therapy for nonalcoholic fatty liver disease in children and adolescents.

Danielle B Andrews, Joel E Lavine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22149573      PMCID： PMC3285489          DOI： 10.1586/egh.11.72

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


× No keyword cloud information.
  16 in total

1.  Histopathology of pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Cynthia Behling; Robert Newbury; Reena Deutsch; Caroline Nievergelt; Nicholas J Schork; Joel E Lavine
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

2.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

3.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

4.  Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.

Authors:  R Dohil; S Schmeltzer; B L Cabrera; T Wang; J Durelle; K B Duke; J B Schwimmer; J E Lavine
Journal:  Aliment Pharmacol Ther       Date:  2011-03-13       Impact factor: 8.171

5.  The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.

Authors:  A E Feldstein; P Charatcharoenwitthaya; S Treeprasertsuk; J T Benson; F B Enders; P Angulo
Journal:  Gut       Date:  2009-07-21       Impact factor: 23.059

6.  Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Authors:  Joel E Lavine; Jeffrey B Schwimmer; Jean P Molleston; Ann O Scheimann; Karen F Murray; Stephanie H Abrams; Philip Rosenthal; Arun J Sanyal; Patricia R Robuck; Elizabeth M Brunt; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2009-09-15       Impact factor: 2.226

7.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Authors:  Valerio Nobili; Melania Manco; Rita Devito; Vincenzo Di Ciommo; Donatella Comparcola; Maria Rita Sartorelli; Fiorella Piemonte; Matilde Marcellini; Paul Angulo
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 8.  Advances in pediatric nonalcoholic fatty liver disease.

Authors:  Rohit Loomba; Claude B Sirlin; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

9.  Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Perrie E Pardee; Joel E Lavine; Aaron K Blumkin; Stephen Cook
Journal:  Circulation       Date:  2008-06-30       Impact factor: 29.690

10.  Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.

Authors:  Heather M Patton; Joel E Lavine; Mark L Van Natta; Jeffrey B Schwimmer; David Kleiner; Jean Molleston
Journal:  Gastroenterology       Date:  2008-09-03       Impact factor: 22.682
View more
  2 in total

1.  Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway.

Authors:  Tingting Ren; Chao Huang; Mingliang Cheng
Journal:  Oxid Med Cell Longev       Date:  2014-11-27       Impact factor: 6.543

2.  Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway.

Authors:  Yi Guo; Jun-Xiang Li; Yun-Liang Wang; Tang-You Mao; Chen Chen; Tian-Hong Xie; Ya-Fei Han; Xiang Tan; Hai-Xiao Han
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-28       Impact factor: 2.629
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.